% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

  • skyhigh_x skyhigh_x Jan 30, 2013 4:07 PM Flag

    NEWS !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

    Celsion Corporation to Host Conference Call and Webcast on January 31, 2013 at 8:00 AM EST to Present Top-Line Data from its Pivotal Phase III HEAT Study
    Last update: 1/30/2013 4:05:00 PM

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • LAWRENCEVILLE, N.J., Jan. 30, 2013 /PRNewswire via COMTEX/ -- Celsion Corporation (CLSN), a leading oncology drug development company, today announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Thursday, January 31, 2013 to present the top-line results from its pivotal Phase III HEAT Study with ThermoDox� in combination with radiofrequency ablation (RFA) in patients with intermediate hepatocellular carcinoma (HCC) versus those patients receiving RFA alone.
      The HEAT Study, which has enrolled a total of 701 patients at 79 sites in 11 countries, has been designated as a Priority Trial for liver cancer by the National Institutes of Health, has received Fast Track Designation from the FDA and has received Orphan Drug Designation in both the U.S. and Europe.
      Conference Call
      The conference call may be accessed by dialing 1-888-466-4462 (Toll-Free/North America) or 1-719-457-2627 (International/Toll) and ask for the Celsion Corporation Phase III HEAT Study Conference Call approximately 10 minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at .
      The call will be archived for replay at 2 p.m. EST on January 31, 2013, and will remain available until February 14, 2013. The replay can be accessed at 1-877-870-5176 (Toll-Free/North America) or 1-858-384-5517 (International/Toll) using Conference ID: 4540212. An audio replay of the call will also be available on the Company's website, , for 30 days after 2 p.m. EST on Friday, January 31, 2013.
      About the HEAT Study
      HEAT (Hepatocellular Carcinoma Study of RFA and ThermoDox�) was an international, multi-center, randomized, placebo-controlled study that randomized 701 patients with intermediate (tumor size 3 cm to 7 cm), unresectable HCC to 50mg/m2 ThermoDox� plus RFA or RFA alone. The primary endpoint of the study was progression-free survival, as defined by the Special Protocol Assessment agreed to with the U.S. FDA. Safety and tolerability were also evaluated.
      The HEAT Study, the largest clinical trial to date in patients with intermediate HCC, was conducted at 79 clinical sites around the world, including the United States, Canada, Italy, China, Taiwan, Hong Kong, Korea, Thailand, Malaysia and the Philippines.
      About Hepatocellular Carcinoma

1.22+0.01(+0.83%)Sep 30 4:00 PMEDT